<?xml version="1.0" encoding="UTF-8"?>
<p id="Par88">The co-administration of ribavirin with intravenous immunoglobulins (IVIG), with specific anti-RSV immunoglobulins or with pavilizumab is currently still poorly defined. However, there is a general consensus that a late start of the therapy, when pulmonary symptoms have already established, compromises its effectiveness [
 <xref ref-type="bibr" rid="CR48">48</xref>]. For PiV, the use of antiviral agents such as ribavirin, intravenous immunoglobulins or a combination of these drugs does not have a significant impact on reducing the length of hospital stay, the duration of symptoms and mortality. Very few new antiviral drugs have shown promising results for the treatment of PIV infection in this type of patient [
 <xref ref-type="bibr" rid="CR29">29</xref>].
</p>
